Skip to main content

Table 2 HCV prevalence by risk factors among French DUs*

From: A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design

  

Prevalence of HCV

Prevalence Ratio

95% Confidence Interval

Missing data

Age

<30 years

    
 

≥ 30 years

67.45

2.43

2.04–3.60

4

Situation

Single

64.96

   
 

In couple

47.38

0.73

0.72–0.74

3

Type of household

Stable

50.90

   
 

Precarious

67.42

1.32

1.32–1.33

16

Ever been jailed

No

48.00

   
 

Yes

66.11

1.38

1.37–1.39

0

Percieved health (last 6 months)

Good

52.02

   
 

Bad

72.98

1.40

1.39–1.41

0

HIV serology

Negative

55.69

   
 

Positive

94.12

1.69

1.68–1.70

0

Fear of HCV Treatment

No

50.26

   
 

Yes

66.86

1.33

1.32–1.34

2

Injected at least once

No

27.90

   
 

Yes

73.82

2.65

2.58–2.71

0

Shared injection materials in the last month

No

55.96

   
 

Yes

86.17

1.54

1.53–1.55

2

Sexual partner drug user injector (last 6 months)

No

56.38

   
 

Yes

73.30

1.30

1.29–1.31

0

Heroine (last month)

No

64.76

   
 

Yes

38.11

0.59

0.57–0.60

0

Methadone (last month)

No

54.17

   
 

Yes

72.82

1.34

1.34–1.35

0

Moscontin (last month)

No

57.21

   
 

Yes

78.69

1.38

1.36–1.39

0

Crack (last month)

No

53.75

   
 

Yes

71.51

1.33

1.32–1.34

0

Substitution therapy (last 6 months)

No

31.77

   
 

Yes

67.75

2.13

2.07–2.20

0

  1. * ANRS-Coquelicot study, France, 2004–2005 (N = 817 DUs who consented to be tested)